MedPath

The prospective study of absolute quantitation of KRAS mutaition in cell free plasma DNA with pancreatic ductal adenocarcinoma.

Not Applicable
Recruiting
Conditions
pancreatic cancer
Registration Number
JPRN-UMIN000017586
Lead Sponsor
Hiroshima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects who have another malignancies simultaneously. 2)Subjects who is participating in another clinical trial affect to primary or secondary end-point of this study 3)Subjects whose Hb levels were less than 7 g/dL 4)Subject who is judged to be ineligible due to subject's background, physical findings, medical examination, physical and clinical examination by principal investigator or sub investigator.

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath